論文

査読有り
2017年2月

Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma

GYNECOLOGIC ONCOLOGY
  • Koji Matsuo
  • Malcolm S. Ross
  • Stephen H. Bush
  • Mayu Yunokawa
  • Erin A. Blake
  • Tadao Takano
  • Yutaka Ueda
  • Tsukasa Baba
  • Shinya Satoh
  • Masako Shida
  • Yuji Ikeda
  • Sosuke Adachi
  • Takuhei Yokoyama
  • Munetaka Takekuma
  • Satoshi Takeuchi
  • Masato Nishimura
  • Keita Iwasaki
  • Shiori Yanai
  • Merieme M. Klobocista
  • Marian S. Johnson
  • Hiroko Machida
  • Kosei Hasegawa
  • Takahito M. Miyake
  • Tadayoshi Nagano
  • Tanja Pejovic
  • Mian M. K. Shahzad
  • Dwight D. Im
  • Kohei Omatsu
  • Frederick R. Ueland
  • Joseph L. Kelley
  • Lynda D. Roman
  • 全て表示

144
2
開始ページ
329
終了ページ
335
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.ygyno.2016.11.042
出版者・発行元
ACADEMIC PRESS INC ELSEVIER SCIENCE

Objective. To examine tumor characteristics and survival outcome of women with uterine carcinosarcoma who had a history of tamoxifen use.
Methods. This is a multicenter retrospective study examining stage I-IV uterine carcinosarcoma cases based on history of tamoxifen use. Patient demographics, tumor characteristics, treatment pattern, and survival outcomes were compared between tamoxifen users and non-users.
Results. Sixty-six cases of tamoxifen-related uterine carcinosarcoma were compared to 1009 cases with no history of tamoxifen use. Tamoxifen users were more likely to be older (mean age, 69 versus 64, P < 0.001) and had a past history of malignancy (100% versus 12.7%, P < 0.001). Tamoxifen-related uterine carcinosarcoma was significantly associated with a higher proportion of stage IA disease (48.4% versus 29.9%) and a lower risk of stage IVB disease (7.8% versus 16.0%) compared to tamoxifen-unrelated carcinosarcoma (P = 0.034). Deep myometrial tumor invasion was less common in uterine carcinosarcoma related to tamoxifen use (28.3% versus 48.8%, P = 0.002). On univariate analysis, tamoxifen use was not associated with progression-free survival (5-year rates 44.5% versus 46.8%, P = 0.48) and disease-specific survival (64.0% versus 59.1%, P = 0.39). After adjusting for age, past history of malignancy, stage, residual disease status at surgery, and postoperative treatment patterns, tamoxifen use was not associated with progression-free survival (adjusted-hazard ratio 0.86, 95% confidence interval 0.50 to 1.50, P = 0.60) and disease-specific survival (adjusted-hazard ratio 0.68, 95% confidence interval 0.36 to 1.29, P = 0.24).
Conclusion. Our study suggests that tamoxifen-related uterine carcinosarcoma may have favorable tumor characteristics but have comparable stage-specific survival outcomes compared to tamoxifen-unrelated uterine carcinosarcoma. (C) 2016 Elsevier Inc. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.ygyno.2016.11.042
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000392885200021&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.ygyno.2016.11.042
  • ISSN : 0090-8258
  • eISSN : 1095-6859
  • Web of Science ID : WOS:000392885200021

エクスポート
BibTeX RIS